An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80 6946 to Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Copanlisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer
- 01 Oct 2016 Status changed from active, no longer recruiting to completed according to the results published in the Annals of Oncology .
- 01 Oct 2016 Results published in the Annals of Oncology (2016).
- 16 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.